Date: Aug 01, 2010 Source: pharmamedtechbi.com (
click here to go to the source)
Cypress purchases carbetocin autism candidate from Marina
Deal Date: Aug-01-2010 / Deal Update Date (Latest): Dec-01-2013 / Deal # 201020369
Executive Summary
RNAi therapeutics company Marina Biotech Inc. has sold its Phase I intranasal autism candidate carbetocin--as well as related product data, contracts, IP, and technology--to Cypress Bioscience Inc. (pain therapeutics and rheumatology drug monitoring).
